In a captivating discussion, Tom Chalberg, Founder and CEO of Genascence, shares his journey from academia to leading innovations in gene therapy. He dives into the evolution of gene treatment, focusing on addressing widespread conditions like osteoarthritis. The conversation reveals the complexities of navigating regulatory landscapes for common vs. rare diseases. Chalberg also discusses the exciting breakthroughs in gene therapy and the strategic partnerships critical for funding in today’s biotech climate, painting a vivid picture of the industry's future.
The evolution of gene therapy is shifting focus from rare diseases to common conditions like osteoarthritis, aiming to improve public health outcomes.
Dr. Tom Chalberg's journey highlights the integration of academic research into the biotech industry, emphasizing the role of entrepreneurial spirit amidst financial challenges.
Deep dives
Transforming Gene Therapy for Common Conditions
A significant shift in gene therapy aims to make treatments accessible for common conditions like osteoarthritis, rather than being limited to rare diseases. The approach focuses on harnessing advancements in genetics to create effective therapies that can also address broader public health issues. By moving gene therapy from academic research into everyday healthcare, there’s potential to alleviate the burden faced by millions suffering from conditions currently managed only with pain control or temporary relief. This transformation is spearheaded by innovative thinkers like Dr. Tom Chalberg, who highlight the necessity of reorienting focus toward prevalent disorders.
Career Journey from Academia to Entrepreneurship
Dr. Tom Chalberg’s career trajectory exemplifies the integration of academic research with the biotech industry, transitioning from genetic research in academia to commercial roles at Genentech. His interest in genetic medicines developed during his graduate studies, which propelled him toward opportunities in the pharmaceutical landscape. Despite the financial turbulence of 2008, he embraced the entrepreneurial spirit and co-founded Avalanche, showcasing resilience and foresight in the biotech sector. This transition underscores how scientific expertise can inform and drive successful biopharmaceutical ventures.
Navigating the Biotech Investment Landscape
The current investment climate in biotech is characterized by increased selectivity among investors, impacted by economic fluctuations and changing interest rates. While many investors express hesitation towards specific indications like osteoarthritis, the significant patient population and unmet needs create compelling opportunities for innovative treatments. Dr. Chalberg emphasizes the importance of aligning with investors who share a long-term vision and can provide patient capital during challenging periods. Therefore, understanding investor motivations and engaging in open communication around scientific advancements can enhance partnership prospects.
Challenges in Gene Therapy Regulation and Distribution
Developing gene therapies for common diseases presents unique regulatory and logistical challenges distinct from those faced in rare conditions. Although the regulatory framework for gene therapies in common diseases involves more rigorous safety evaluations, experiences with vaccines lay the groundwork for effective oversight in larger populations. Furthermore, the economics of gene delivery must be navigated to ensure affordability, requiring lower manufacturing costs to align with common disease treatment pricing battles. Addressing the complexities of distribution and ensuring accessibility without exorbitant costs remains a strategic focus for companies pursuing gene therapies for widespread conditions.
Recorded in-person at the JP Morgan Healthcare Conference in San Franscisco, this episode finds Matt Pillar and Ben Comer exploring the evolution of gene therapy with Dr. Tom Chalberg, Founder, Chairman, & CEO at Genascence. We discuss ATMPS' transition from treating rare diseases to addressing common conditions like osteoarthritis, share insights on the delivery mechanism and regulatory challenges in the space, and get into the nuts and bolts of the Genascence partnership strategy.
The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.